CPMP konkluderede derfor, at risk/ benefit- forholdet i forbindelse med cerivastatin er negativt ved normal brug i alle tidligere tilladte doser.
The CPMP therefore concluded that the balance of risks and benefits for cerivastatin is negative under normal conditions of use at all previously authorised doses.